Tempus AI Strengthens its Business Through Acquisitions and new Offerings. The AI Solutions aim to Advance Personalized Medicine.
Reading Time: 2 minutes
The rise of tech stocks initially occurred on Monday (March 24) under decreasing volume. In contrast, the stock of Tempus AI (TEM) was able to increase by double digits under increased volume. Tempus AI has established itself as a leading company in personalized medicine and collaborates with 95% of the top 20 pharmaceutical oncology companies. The company is represented in about 65% of academic medical centers and offers three main products: genomics, data, and AI applications. In November 2024, Tempus announced the acquisition of Ambry Genetics...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
